The DMG aims to provide optimum and multi disciplinary care of
urological cancers based on maximum adherence to evidence based medicine protocols.
The cancers treated under this disease management group are – Prostate cancer, Testicular cancer, kidney cancer, Urinary bladder cancer, Penile cancer & adrenal tumors. The patients are appropriately evaluated for the disease and once staging is complete, treatment options are discussed. The best possible treatment decision is then made.
For evaluation we have a NABL accredited laboratory which does almost all investigations including tumor markers, cytology and microbiology. We have advanced Uro-onco pathology services with several immune-histochemistry and molecular markers being assessed with multiple techniques. We make use of appropriate CT scan, MRI scan and PET scans – FDG PET scan and PSMA PET scan [for prostate cancer] as applicable in evaluation. All these facilities are provided at Tata Memorial Hospital.
We do provide open and minimally invasive – laparoscopic and robotic surgical procedures to patients at a very affordable cost. Wherever possible, we try doing organ preserving surgeries – for eg. partial nephrectomy, penile preserving surgeries, The DMG also offers state of art radiation therapy – stereotactic hypofractionated and Image guided for prostate cancer, Urinary bladder cancers and testicular seminomatous cancers. Bladder preservation protocols for urinary bladder cancers are offered in selected patients. Medical oncology services offer chemotherapy and molecular therapy to cases of advanced cancer.
Stereotactic Body Radiation Therapy (SBRT) has been introduced for prostate
cancer which significantly reduces treatment time to 5-7 days from 5-7 weeks, with minimal toxicity, greatly improves convenience on patients and reduces burden on therapy machines.
General OPD - Tues / Thurs
Timing - 09:15 – 17:30 Hours
Location - Golden Jubilee Building , Ground Floor Room No. 57
Private OPD - Tues / Thurs
Timing - 09:15 – 17:30 Hours
Location - Homi Bhabha Building , Room No. 214.
The trainees are MBBS/ MD/MS qualified doctors who are admitted to various course specialties like Surgical Oncology, Medical Oncology, Radiation Oncology, Pathology, Nuclear Medicine, Radio diagnosis on the basis of their marks obtained in the Maharashtra state CET/NEET examination.
Observers: Medical students from other universities and institutions are accepted as observers in different departments of the Uro-oncology DMG. They use this opportunity to get familiar to working of a multi-disciplinary Uro-oncology team. Due to the high volume of patients coming to the hospital, it helps in learning the various aspects of Urological cancers including clinical presentations, evaluation, staging and management.
The faculty also participates in Onco nursing training program, Stoma clinic workshops and hospital infection related workshops.
Continuing Medical Education (CME) Programme for Post-graduate students and practicing doctors: Uro-oncology DMG has been conducting an Annual CME since 2012. Large number of doctors take advantage of this meeting to update themselves in Urooncology topics. Few of the themes, which we had were -
Year | Theme |
---|---|
2012 | Testicular tumors |
2013 | Bladder Cancers |
2014 | Nuclear Imaging in Urology |
2015 | Prostate Cancer Masterclass |
2016 | Renal cell carcinoma |
2017 | Penile and Urethral Cancer, an update |
1 | 1352 | Germ Cell tumor out come and long term follow up study (GTOF) |
Dr Amit Joshi | Ongoing |
2. | ACTREC 79 |
Kidney Cancer Registry | Dr Amit Joshi | Ongoing |
3. |
1720 | A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia. |
Dr Amit Joshi | Ongoing |
4. . | 1458 | Hormone receptor status in adrenocortical carcinomas |
Dr Ganesh Bakshi |
Completed |
5. | 932 | Prospective Phase III randomized trial of prostate only or whole pelvic radiotherapy in high risk prostate cancer (POP-RT trial) |
Dr Vedang Murthy |
Ongoing |
6. | 1467 | Elucidating the role of Surfactant Protein D in Prostate cancer |
Dr Gagan Prakash |
Ongoing |
7. | 590 | Feasibility study evaluating bladder preservation by helical tomotherapy based IMRT in muscle invasive bladder cancer. |
Dr Vedang Murthy |
Ongoing |
8. | 1724 | Study of Nephron Sparing Surgeries at Tata Memorial Hospital |
Dr Ganesh Bakshi |
Ongoing |
9. | 1414 | Protocol No. RLS/0314/020- A two stage, randomized, multicentric, open label, multiple dose, two- treatment, two sequence, two- period, crossover, steady state bioequivalence study of test Nilutamide 150 Mg tablets (from EirGen Pharma Ltd., Ireland) with reference Nilandron 150 mg tablets of Sanofiaventis U.S. LLC in prostate cancer patients under fasting condition. |
Dr Vikram Gota |
Completed |
10. | 1555 | To evaluate the role of 68GaPMSA PET/CT in detection of recurrent disease in prostate cancer. |
Dr Venkatesh Rangarajan |
Ongoing |
11. | 1753 | Retrospective audit to find the incidence of adrenal masses in CT scans done for other indications (incidentalomas) at Tata Memorial Centre |
Dr Nilesh Sable |
Ongoing |
12. | ACTREC 176 |
Best Adjuvant Chemotherapy for use in Penile carcinoma |
Dr Vanita Noronha |
Ongoing |
13. | ACTREC 154 |
To study the feasibility of therapeutic drug monitoring of sunitinib in metastatic Renal cell carcinoma |
Dr Vikram Gota |
Ongoing |
14. | ACTREC 28 |
Identification of Men with a genetic predisposition to Prostate cancer: Targeted screening in BRCA 1 /2 mutation carriers and controls. The IMPACT Study. |
Dr Vedang Murthy |
Ongoing |
15. | ACTREC 194 |
Prospective randomized trial of Adjuvant radiotherapy following surgery and chemotherapy in muscle invasive transitional cell carcinoma of urinary bladder (BART) |
Dr Vedang Murthy |
Ongoing |
16. | ACTREC 111 |
The circulating micro RNA in diagnosis and progression of prostate cancer. |
Dr Vedang Murthy |
Ongoing |
17. | 1813 | Clinical Outcome Of Prostatic Cancer Patients Treated With Intensity Modulated Radiation Therapy (IMRT) And Moderate Hypo-Fractionation - A Retrospective Analysis |
Dr Umesh Mahantshetty |
Ongoing |
18. | 1854 | An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed with Advanced Hormone-dependent Prostate Cancer (FIRST) |
Dr Ganesh Bakshi |
Approved by IEC, to be initiated |
19. | ACTREC 261 |
Exploring the utility of circulating tumor DNA in monitoring response to therapy and in aiding follow up of prostate cancer patients using the palliative systemic therapy in hormone sensitive prostate cancer setting as a model. |
Dr Vanita Noronha |
Submitted to IEC 3, Initial comments received, Due for resubmission to IEC 3 |
Apart from the above mentioned studies, many questionnaire based studies and service audits are done to help improve the services
Department Office Number: (+9122) 24177000 / Ext.No. 7188, 7418, 7176/
MOBILE No. SR II/III: 22440
Department of Urology,
TATA MEMORIAL HOSPITAL, Dr.E.Borges Road, Parel, Mumbai-400-012
Maharashtra, India
Hospital Fax Number: (+9122) 24101656
Email-id: dmguro@tmc.gov.in
TATA MEMORIAL HOSPITAL
Dr. E Borges Road, Parel, Mumbai - 400 012 India
Phone: +91-22- 24177000, 24177300, 24161413
Fax: +91-22-24146937
E-mail : msoffice@tmc.gov.in(for patient care and queries)/cash@tmc.gov.in(for accounts related)/fundraising@tmc.gov.in (for donors and donation related)/registrar@tmc.gov.in(for education and training)/hrd@tmc.gov.in(for administrative - HRD matters) This email address is being protected from spambots. You need JavaScript enabled to view it.
Copyright © 2016 Tata Memorial Centre. All rights reserved.This website can be best viewed in Microsoft Internet Explorer 9.0+, Chrome, Firefox
Designed and Developed by Mindspace Software Technologies Pvt. Ltd.
1155459 (58)